ArticleScientific reports2025
Molecular profiling and bioinformatics validation of CEACAM6, HOXA-AS3 and miR29a in colorectal cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role and Mechanism of G Protein Subunit Alpha-15 in Colorectal Cancer: An Analysis of Two Hundred Eight Patient Samples and Public Datasets.World journal of oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Colorectal cancer (CRC) is a leading causes of cancer-related mortality worldwide. Dysregulated expression of specific genes and non-coding RNAs contributes to CRC progression. This study investigated the expression and clinical relevance of CEACAM6, HOXA-AS3, and miR-29a in CRC, combining experimental data with bioinformatics analysis to assess their diagnostic and prognostic value. Tissue samples from 68 CRC patients (tumor and adjacent normal) were analyzed for CEACAM6, HOXA-AS3, and miR-29a expression by real-time PCR. Bioinformatics validation using TCGA, GEPIA, and ENCORI databases assessed expression, interactions, and assess clinical associations. CEACAM6 and miR-29a were significantly upregulated, while HOXA-AS3 was downregulated in CRC tissues compared to normal counterparts. Notably, miR-29a also showed elevated expression levels in patient serum samples (p < 0.05). Among the examined markers, CEACAM6 expression varied significantly with tumor differentiation status (p < 0.05). Serum levels of IL-6 were significantly increased in CRC patients (p < 0.05). Receiver operating characteristic (ROC) analysis demonstrated high diagnostic accuracy for miR-29a (AUC = 0.918). A significant positive correlation was observed between miR-29a expression in serum and tumor tissue (p = 0.038). Additionally, in silico analysis suggested regulatory interactions between HOXA-AS3 and the mRNAs of CEACAM6 and IL-6. CEACAM6, HOXA-AS3, and miR-29a may serve as promising biomarkers for early detection and prognosis of CRC. Integrating molecular profiling with bioinformatics validation provides a robust approach to uncover clinically relevant targets in CRC. The correlation between serum and tumor tissue miR-29a expression highlights its potential utility in liquid biopsy approaches for CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.